All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130. We investigated the in vivo antinephritic effect of ATRA on IL-6 transgenic mice which had developed mesangial proliferative glomerulonephritis (PGN) as well as its in vitro inhibitory effect on the proliferation of rat mesangial cells. In vivo experiments on IL-6 transgenic mice showed that ATRA administration suppressed proteinuria and hematuria and reduced the IL-6 concentrations; furthermore, histological examination demonstrated that it improved PGN. In vitro experiments using rat mesangial cells demonstrated that ATRA inhibited cell growth in a dose-dependent manner within a range from 10–4 to 10–6M. This inhibition by ATRA was partially counteracted by the addition of IL-6. RT-PCR assay results showed that ATRA also reduced IL-6R, but not the glycoprotein 130 expression in mesangial cells. These findings indicate that, by blocking of the IL-6 function, ATRA may be therapeutically effective in PGN.

1.
Chida Y, Tomura S, Takeuchi J: Renal survival rate of IgA nephropathy. Nephron 1985;40:189–194.
[PubMed]
2.
D’Amico G, Imbasciati E, Barbiano Di Belgioioso GB, Bertoli S, Fogazzi G, Ferrario F, Fellin G, Ragni A, Colasanti G, Minetti L, Ponticelli C: Idiopathic IgA mesangial nephropathy: Clinical and histological study of 374 patients. Medicine (Baltimore) 1985;64:49–60.
[PubMed]
3.
Leaker B, Fairley KF, Dowling J, Kincaid-Smith P: Lupus nephritis: Clinical and pathological correlation. Q J Med 1987;62:163–179.
4.
Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J: Kidney biopsy in SLE. I. A clinical-morphologic evaluation. Q J Med 1989;73:1125–1133.
5.
Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE: Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 1995;4:109–115.
[PubMed]
6.
Wagner J, Dechow C, Morath C, Lehrke I, Amann K, Waldherr R, Floege J, Ritz E: Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000;11:1479–1487.
[PubMed]
7.
Morath C, Dechow C, Lehrke I, Haxsen V, Waldherr R, Floege J, Ritz E, Wagner J: Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001;12:2300–2309.
[PubMed]
8.
Dechow C, Morath C, Peters J, Lehrke I, Waldherr R, Haxsen V, Ritz E, Wagner J: Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol 2001;281:F909–F919.
9.
Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T: Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040–3046.
[PubMed]
10.
Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78.
[PubMed]
11.
Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, Yoshizaki K, Hirano T, Kishimoto T: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989;143:3949–3955.
[PubMed]
12.
Eitner F, Westerhuis R, Burg M, Weinhold B, Gröne HJ, Ostendorf T, Rüther U, Koch KM, Rees AJ, Floege J: Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 1997;51:69–78.
[PubMed]
13.
Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki S, Yamamura K, Hirano T, Kishimoto T: IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989;86:7547–7551.
[PubMed]
14.
Dohi K, Iwano M, Muraguchi A, Horii Y, Hirayama T, Ogawa S, Shiiki S, Hirano T, Kishimoto T, Ishikawa H: The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol 1991;35:1–5.
[PubMed]
15.
Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H, Fukatsu A, Matsuda T, Hirano T, Kishimoto T, Ishikawa H: Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993;40:16–21.
[PubMed]
16.
Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y: Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304–311.
[PubMed]
17.
Bronstein I, Edwards B, Voyta JC: 1,2-Dioxetanes: Novel chemiluminescent enzyme substrates. Applications to immunoassays. J Biolumin Chemilumin 1989;4:99–111.
[PubMed]
18.
Foidart JB, Dechenne CA, Mahieu P, Creutz CE, de Mey J: Tissue culture of normal rat glomeruli: Isolation and morphological characterization of two homogeneous cell lines. Invest Cell Pathol 1979;2:15–26.
[PubMed]
19.
Hazen-Martin DJ, Chao CC, Wang IY, Sens DA, Garvin AJ, Wang AC: Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms. Pediatr Pathol 1993;13:37–52.
[PubMed]
20.
Argiles A, Mourad G, Basset N, Axelrud-Cavadore C, Haiech J, Mion C, Cavadore JC, Demaille JG: Acute adaptive changes to unilateral nephrectomy in humans. Kidney Int 1987;32:714–720.
[PubMed]
21.
Jacques EA, Buschmann RJ, Layden TJ: The histopathologic progression of vitamin A-induced hepatic injury. Gastroenterology 1979;76:599–602.
[PubMed]
22.
Miyazaki J, Appella E, Ozato K: Negative regulation of the major histocompatibility class I gene in undifferentiated embryonal carcinoma cells. Proc Natl Acad Sci USA 1986;83:9537–9541.
[PubMed]
23.
Takitani K, Tamai H, Morinobu T, Kawamura N, Miyake M, Fujimoto T, Mino M: Pharmacokinetics of all-trans retinoic acid in pediatric patients with leukemia. Jpn J Cancer Res 1995;86:400–405.
[PubMed]
24.
Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RA: TGF-beta stimulates rat mesangial cell proliferation in culture: Role of PDGF beta-receptor expression. Am J Physiol 1993;264(2 Pt 2):F199–F205.
25.
Patel P, Varghese E, Ding G, Fan S, Kapasi A, Reddy K, Franki N, Nahar N, Singhal P: Transforming growth factor beta induces mesangial cell apoptosis through NO- and p53-dependent and -independent pathways. J Investig Med 2000;48:403–410.
[PubMed]
26.
Brinckerhoff CE, Sheldon LA, Benoit MC, Burgess DR, Wilder RL: Effect of retinoids on rheumatoid arthritis, a proliferative and invasive non-malignant disease. Ciba Found Symp 1985;113:191–211.
[PubMed]
27.
Kakizaki Y, Kraft N, Atkins RC: Differential control of mesangial cell proliferation by interferon-gamma. Clin Exp Immunol 1991;85:157–163.
[PubMed]
28.
Tan MS, Tsai JC, Lee YJ, Chen HC, Shin SJ, Lai YH, Perrella MA, Bianchi C, Higashiyama S, Endege W, Lee ME, Tsai JH: Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators. Kidney Int 1994;46:690–695.
[PubMed]
29.
Abboud HE, Poptic E, DiCorleto P: Production of platelet-derived growth factor like protein by rat mesangial cells in culture. J Clin Invest 1987;80:675–683.
[PubMed]
30.
Raynaud F, Gerbaud P, Gu XF, Donnadieu M, Evain-Brion D: Effect of retinoic acid on platelet-derived growth factor (PDGF) bioactivity and type-B PDGF receptors in normal and psoriatic human fibroblasts. J Invest Dermatol 1991;96:111–115.
[PubMed]
31.
Krust A, Kastner P, Petkovich M, Zelent A, Chambon P: A third human retinoic acid receptor, hRAR-gamma. Proc Natl Acad Sci USA 1989;86:5310–5314.
[PubMed]
32.
Zelent A, Krust A, Petkovich M, Kastner P, Chambon P: Cloning of murine alpha and beta retinoic acid receptors and a novel receptor gamma predominantly expressed in skin. Nature 1989;339:714–717.
[PubMed]
You do not currently have access to this content.